UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines

PloS one, 2013-09, Vol.8 (9), p.e74768-e74768

2013

Volltextzugriff (PDF)

Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies

Cancer chemotherapy and pharmacology, 2023-08, Vol.92 (2), p.97-105

2023

Volltextzugriff (PDF)

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models

International journal of cancer, 2017-07, Vol.141 (2), p.405-413

2017

Volltextzugriff (PDF)

Retinoid therapy of high-risk neuroblastoma

Cancer letters, 2003-07, Vol.197 (1), p.185-192

2003

Volltextzugriff (PDF)

Hydrophilic interaction liquid chromatography–tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019-04, Vol.1112, p.16-23

2019

Volltextzugriff (PDF)

DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer

Biochimica et biophysica acta. Gene regulatory mechanisms, 2023-06, Vol.1866 (2), p.194939-194939, Article 194939

2023

Volltextzugriff (PDF)

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors

Cancer chemotherapy and pharmacology, 2021-04, Vol.87 (4), p.525-532

2021

Volltextzugriff (PDF)

Ceramide synthesis and metabolism as a target for cancer therapy

Cancer letters, 2004-04, Vol.206 (2), p.169-180

2004

Volltextzugriff (PDF)

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

Clinical cancer research, 2017-08, Vol.23 (16), p.4550-4555

2017

Volltextzugriff (PDF)

Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts

Molecular cancer therapeutics, 2016-11, Vol.15 (11), p.2653-2664

2016

Volltextzugriff (PDF)

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium

Pediatric blood & cancer, 2013-11, Vol.60 (11), p.1801-1808

2013

Volltextzugriff (PDF)

N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing

Molecular cancer therapeutics, 2008-09, Vol.7 (9), p.2967-2976

2008

Volltextzugriff (PDF)

Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia

Anti-cancer drugs, 2019-02, Vol.30 (2), p.117-127

2019

Volltextzugriff (PDF)

Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

British journal of pharmacology, 2011-07, Vol.163 (6), p.1263-1275

2011

Volltextzugriff (PDF)

Synergistic Cytotoxicity in Solid Tumor Cell Lines Between N-(4-Hydroxyphenyl)retinamide and Modulators of Ceramide Metabolism

JNCI : Journal of the National Cancer Institute, 2000-12, Vol.92 (23), p.1897-1909

2000

Volltextzugriff (PDF)

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity

Journal of molecular medicine (Berlin, Germany), 2013-04, Vol.91 (4), p.459-472

2013

Volltextzugriff (PDF)

Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators

Cancer research (Chicago, Ill.), 2004-08, Vol.64 (15), p.5415-5424

2004

Volltextzugriff (PDF)

Increase of Ceramide and Induction of Mixed Apoptosis/Necrosis by N-(4-Hydroxyphenyl)- retinamide in Neuroblastoma Cell Lines

JNCI : Journal of the National Cancer Institute, 1999-07, Vol.91 (13), p.1138-1146

1999

Volltextzugriff (PDF)

Evaluating response to antineoplastic drug combinations in tissue culture models

Methods in molecular medicine, 2005, Vol.110, p.173

2005

Volltextzugriff (PDF)

Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex

Clinical cancer research, 2007-05, Vol.13 (10), p.3079-3086

2007

Volltextzugriff (PDF)

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study

BMC research notes, 2014-04, Vol.7 (1), p.256-256, Article 256

2014

Volltextzugriff (PDF)

N-(4-hydroxyphenyl) Retinamide Augments Laser-Induced Choroidal Neovascularization in Mice

Investigative ophthalmology & visual science, 2008-03, Vol.49 (3), p.1210-1220

2008

Volltextzugriff (PDF)

Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas

Anticancer research, 2011-03, Vol.31 (3), p.961-966

2011

Volltextzugriff (PDF)

N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase

Cancer research (Chicago, Ill.), 2001-07, Vol.61 (13), p.5102-5105

2001

Volltextzugriff (PDF)

N-(4-hydroxyphenyl) retinamide augments laser-induced choroidal neovascularization in mice

Investigative ophthalmology & visual science, 2008-03, Vol.49 (3), p.1210-1220

2008

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(114)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(138)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines

Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models

Retinoid therapy of high-risk neuroblastoma

Hydrophilic interaction liquid chromatography–tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma

DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors

Ceramide synthesis and metabolism as a target for cancer therapy

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium

N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing

Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia

Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

Synergistic Cytotoxicity in Solid Tumor Cell Lines Between N-(4-Hydroxyphenyl)retinamide and Modulators of Ceramide Metabolism

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity

Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators

Increase of Ceramide and Induction of Mixed Apoptosis/Necrosis by N-(4-Hydroxyphenyl)- retinamide in Neuroblastoma Cell Lines

Evaluating response to antineoplastic drug combinations in tissue culture models

Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study

N-(4-hydroxyphenyl) Retinamide Augments Laser-Induced Choroidal Neovascularization in Mice

Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas

N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase

N-(4-hydroxyphenyl) retinamide augments laser-induced choroidal neovascularization in mice

Suchergebnisse filtern